
The Union Chemicals Minister Ram Vilas Paswan is ready to introduce a new drug policy that will put more than 350 drugs under price control. However, India’s Pharmaceuticals industry has criticized the move of the ministry.
Now, the government of India will face tough time on this matter. Paswan is in preparation to take this policy for discussion in the cabinet.
These are some of the points that places in the proposed drug policy -
# It Puts 354 necessary drugs under controlled price
# This will fix the maximum margin of profit will be fixed. Presently, drug companies cannot sell any drug for more than Rs 250 if it costs Rs 100.
# This margins goes up to 200 percent if the drug develops for drugs developed through aboriginal means.
According to the CNN IBN reports, the Finance Ministry, the Department of Industry and the Planning Commission do not like the proposed policy of price control.
Paswan, it seems, is not going to loose the opportunity to be the champion of the common person. He said that price control is needed, as competition does not keep prices in check.
Now, it will be interesting to see the coming tussle between the Chemicals Ministry and the others in the government. It seems Paswan will certainly give a blow to the UPA government.
Read
Paswan ready to give government a headache with New Drug Policy
Made Popular Aug 16 2006
India :
Add your Comment
Home

Delicious
Digg
Facebook
Reddit
Stumble Upon
Technorati
Mixx
Sphinn
Twitter
SphereIt
Propeller
Gmarks
Newsvine
Yahoo! My Web
Live Journal
Blinklist
E-mail
RSS 






seems to be good for common man,whether the intentions are genuine or political,but the real concern is that the move will discourage and demotivate the pharma giants to pour in heavy sums for R&D and as we all know that at what a great pace our old drugs are getting outdated whereas most of the new drugs approved in recent years are losing their approval due to severe adverse events observed in post marketing surveillence,hence continuos R&D efforts are necessary to cope up the coming future of disease prevalency with effective and safer drugs